Q-omics provides the consensus-scored GOLGA2P10 profile across patient tissues and cancer cell-line models. GOLGA2P10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GOLGA2P10 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, GOLGA2P10 RNA expression shows 18,823 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, and THYM as cancer lineages where GOLGA2P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA2P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA2P10 survival associations across molecular data types. GOLGA2P10 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA2P10 RNA expression–survival associations across cancer types. High GOLGA2P10 expression shows unfavorable associations in LIHC, KIRP, KIRC and KICH, but favorable associations in LGG and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GOLGA2P10 RNA expression.
This table summarizes GOLGA2P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA2P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA2P10 shows lower tumor expression in THCA and higher tumor expression in LIHC, KIRP, CHOL and KIRC. The LIHC box plot shows higher GOLGA2P10 RNA expression in tumor versus normal tissue (log2 FC = +0.877, t-test p < 0.001).
This table shows molecular features associated with GOLGA2P10 in patient tissues and cancer cell lines. In patient samples, GOLGA2P10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
